SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is drawing attention as traders react to a rebound alongside discussion of Midnights mainnet launch and ecosystem developments, including Google Clouds validator role and a reported Coinbase listing. Some see these as signs of growing adoption, while others remain cautious about weak follow-through and selling pressure from token unlocks and airdrops.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs planned acquisition of Grains 800 MHz spectrum has fueled concern that Starlink Mobile could eventually compete with T-Mobile and other wireless carriers. Traders are split between viewing the move as a long-term competitive threat and calling the selloff an overreaction, given the infrastructure needed to build a rival network and T-Mobiles pushback that spectrum alone does not make a network.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp swings are driving the discussion, with traders pointing to a rally they associate with CME futures access and a Grayscale filing, followed by a pullback. Bulls see the moves and BCHs relative resilience as signs of strength, while skeptics question its utility and warn of further declines.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs rally and elevated trading volume are drawing attention as traders look ahead to Patrick Soon-Shiongs Piper Sandler fireside chat, where he is expected to discuss trial progress. The community also cites falling short interest and possible covering, while rumors of a partnership or other undisclosed news remain speculative.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

GEOM is drawing attention around its proposed platform for tokenizing oil and mineral assets and royalties, with traders linking its prospects to Greenland Energy (GLND) and anticipating platform or partner developments. Bullish holders see an early real-world-asset opportunity, while skeptics cite the tokens decline, thin liquidity, and uncertainty about execution.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

The DOJs clearance of Transoceans planned all-stock Valaris merger is a key focus, alongside new contract awards that add to backlog. Traders see potential synergies and elevated short interest as bullish, while others are frustrated by the muted share response and cite debt, dilution, and continued selling pressure.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

A reported burst of JasmyChain transactions consuming JASMY for gas, alongside JLP token activity, is fueling discussion about whether the network is beginning to show real usage. Bulls view it as an early utility signal, while skeptics emphasize that adoption remains limited and debate continued price weakness and exchange delistings.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas proposed first U.S. data-center acquisition and broader AI-infrastructure expansion plan are driving discussion. Many traders welcome the strategic move, while skeptics focus on the non-binding nature of the deal, the lack of disclosed financing, and concerns about dilution and execution of existing projects.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Anticipation around Aerodromes planned merger with Velodrome and expansion into a unified, multichain liquidity platform is a central focus, with traders also watching AEROs move toward the $1 level. Bullish posts see broader reach and protocol activity as potential tailwinds, while others question whether the rollout will deliver or warn of delays, token emissions, and a possible sell-the-news reaction.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances rally is being tied to its stronger commercial outlook and anticipation of upcoming melanoma and sarcoma presentations, earnings, and an NSCLC data update; traders also point to a reported decline in short interest as a possible tailwind. The community is broadly bullish on the catalysts, while some caution that the sharp run-up may bring profit-taking and that clinical results remain uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of 0.00% and +7.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer

AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.

Zacks.com featured highlights include American Outdoor Brands, Cimpress, National Energy Services Reunited, CTO Realty Growth and Kiniksa Pharmaceuticals International 

American Outdoor Brands, Cimpress, National Energy, CTO Realty and Kiniksa stand out for recent price strength backed by earnings growth and estimate revisions.

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$79.78
Prev Close	$78.75
Open	$78.24
Dividend Yield	0.00%
50-Day Moving Average	$77.50
Beta	0.65
Avg. Volume	571,665.82
PE Ratio	81.12

52-Week High	$82.94
52-Week Low	$35.20
Market Capitalization	$6.14B
EPS (Annual)	$0.7471
Price to Book	9.51
Revenue Per Employee	$1.85M

Feed

News

Sentiment

Earnings

Fundamentals

Info

KNSA Fundamentals